Cyclosporine nephrotoxicity in type 1 diabetic patients: A 7-year follow-up study

Diabetes Care

Volumn 22, Issue 3, 1999, Pages 478-483

  Parving, Hans Henrik ^a   Tarnow, Lise ^a   Nielsen, Flemming S ^a   Rossing, Peter ^a   Mandrup Poulsen, Thomas ^a   Østerby, Ruth ^b   Nerup, Jørn ^a  

^a STENO DIABETES CENTER   (Denmark)

^b University Institute of Pathology Arhus   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HEMOGLOBIN A1C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; MALE; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0033009588     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.3.478     Document Type: Article

References (31)

1. Stiller CR, Laupacis A, Keown PA, Gardell C, Dupré J, Thibert P, Wall W: Cyclosporin: action, pharmacokinetics and effect in the BB rat model. Metabolism 32:69-72, 1983
2. Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Roger NW, von Graffenried B, Wolfe BMJ: Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223:1362-1367, 1984
3. Assan R, Debray-Sachs M, Labone C, Chatenoud L, Feutren G, Quiniou-Debrie MC, Thomas G, Bach JF: Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet i:67-71, 1985
4. The Canadian-European Randomized Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention. Diabetes 37:1574-1582, 1988
5. Assan R, Feutren G, Sirmai J, Laborie C, Boitard C, Vexiau P, Du Rostu H, Rodier M, Figoni M, Vague P: Plasma C-peptide levels and clinical remissions in recent onset type 1 diabetic patients treated with cyclosporin A and insulin. Diabetes 39:768-774, 1990
6. Myers BD: Cyclosporine nephrotoxicity. Kidney Int 30:964-974, 1986
7. Myers BD, Sibley R, Newton L, Tomlanovich S, Boshkos C, Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS, Perlroth MG: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33:590-600, 1988
8. Mihatsch MJ, Helmchen U: Kidney biopsy findings in cyclosporine-treated patients with insulin-dependent diabetes mellitus. Klinische Wochenschrift 69:354-359, 1991
9. Feutren G, Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326:1654-1660, 1992
10. Fioretto P, Steffes MW, Mihatsch MJ, Strom EH, Sutherland DER, Mauer SM: Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 48:489-495, 1995
11. Myers BD, Ross J, Newton L, LuetscherJA, Perlroth MG: Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699-705, 1984
12. Myers BD, Newton L: Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol 2:S45-S52, 1991
13. De Filippo G, Carel J-C, Boitard C, Bougnères P-F: Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 45101-104, 1996
14. lc by thin layer isoelectric focusing. J Chromatogr 182:325-333, 1980
15. Feldt-Rasmussen B, Dinesen B, Decken M: Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45:539-544, 1985
16. Jensen T, Decken M, Dawnay A, Feldt-Rasmussen B: Micro-ELISA for the quantitation of human urinary and serum retinol-binding protein. Diabetes Res 10:93-95, 1989
17. Larsen K: Creatinine assay by a reaction: kinetic principle. Clin Chim Acta 41:209-217, 1972
18. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
19. Østerby R: Early phases in the development of diabetic glomerulopathy: a quantitative electron microscopic study. Acta Med Stand 574 (suppl): 1-80, 1975
20. Feldt-Rasmussen B, Jensen T, Dieperink H, Mandrup-Poulsen T, Nerup J, Bendtzen K, Andersen V, Kemp E, Leyssac PP: Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus. Diabet Med 7:429-433, 1990
21. Hansen JM, Fogh-Andersen N, Christensen NJ. Strandgaard S: Cyclosporine-induced hypertension and decline in renal function in healthy volunteers. J Hypertens 15:319-326, 1997
22. Mark AL: Cyclosporine, sympathetic activity, and hypertension. N Engl J Med 323: 748-750, 1990
23. Sturrock NDC, Lang CC, Baylis PH, Struthers AD: Sequential effects of cyclosporine therapy on blood pressure, renal function and neurohormones. Kidney Int 45:1203-1210, 1994
24. Lee DBN: Cyclosporine and the reninangiotensin axis. Kidney Int 52:248-260, 1997
25. Hannedouche TP, Natov S, Boitard C, Lacour B, Grünfeld J-P: Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes. Nephrol Dial Transplant 11:673-678, 1996
26. Rossing P, Astrup A-S, Smidt UM, Parving H-H: Monitoring kidney function in diabetic nephropathy. Diabetologia 37:708-712, 1994
27. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen ST: Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 536:531-535, 1997
28. Parving H-H, Østerby R, Anderson PW, Hsueh WA: Diabetic nephropathy. In The Kidney. 5th ed. Brenner BM, Ed. Philadelphia, Saunders, 1996, p. 1864-1892
29. Parving H-H: Initiation and progression of diabetic nephropathy. N Engl J Med 335:1682-1683, 1996
30. Microalbuminuria Collaborative Study Group UK: Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 306:1235-1239, 1993
31. Gall M-A, Hougaard P, Borch-Johnsen K, Parving H-H: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314:783-788, 1997